sglt2 inhibitors and glp 1 agonist GLP-1 receptor agonists inhibitors: a couple at last? SGLT-2 inhibitors, GLP-1 receptor agonists,

Although the specific molecular mechanisms through which obesity promotes carcinogenesis remain not fully elucidated, epidemiological studies indicate that approximately 48% of malignant tumors can be attributed to obesity, and obesity serves as an independent risk factor for poor prognosis in cancer patients [54]

These drugs are also used to reduce the risk of heart disease and kidney damage

As such, the AMYR agonists (combined with other incretin class members) could represent the elusive drug candidate to address the multi-hormonal dysregulations of diabetes subtypes and qualify as a precision medicine approach that surpasses the long overdue division into T1DM and T2DM

Huang Y

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus | Pfizer